Application of newly synthesized 1-34 human parathyroid hormone for diagnostic tests.
1-34 human parathyroid hormone (1-34 hPTH) was synthesized by a liquid-phase method and prepared for clinical use (specific activity, 3281 U/mg). With this preparation, the toxicity was studied in 22 normal volunteers and the metabolic effects in 15 individuals. Intradermal administration of 4 ng of 1-34 hPTH caused neither abnormal local skin reactions nor toxicity in terms of subjective and objective parameters. When administered intravenously at doses of from 2 to 20 microgram as a bolus, the preparation caused no acute or subacute toxicity judging from the results of various clinical and laboratory studies, except for transient mild hypotension and headache in a minority of subjects. For diagnostic use, 20 microgram of 1-34 hPTH administered intravenously was found to produce effects almost equivalent to those of 200 USPU U of Parathormone (PTE, Eli Lilly). Thus, the criteria for differentiation of hypoparathyroidism from pseudo-hypoparathyroidism devised with 2000 USP U of PTE as a test substance was found to be applicable when 20 microgram of 1-34 hPTH was utilized.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002417:Cattle; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007011:Hypoparathyroidism / Q000175:diagnosis*; D007275:Injections, Intravenous; D010280:Parathyroid Glands / Q000502:physiology; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D011547:Pseudohypoparathyroidism / Q000175:diagnosis; D012882:Skin Tests; D019379:Teriparatide; D013997:Time Factors; D014020:Tissue Extracts; D014808:Vitamin D Deficiency / Q000175:diagnosis
D010281:Parathyroid Hormone; D010446:Peptide Fragments; D014020:Tissue Extracts; D019379:Teriparatide